East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nitroglycerin Sublingual Tablets, USP, 0.3 mg, 0.4 mg, and 0.6 mg. Aurobindo Pharma’s Nitroglycerin Sublingual Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Nitrostat® Sublingual Tablets manufactured by Viatris Specialty LLC.

Nitroglycerin Sublingual Tablets are indicated for:

• The acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.